"Dvo\u0159\u00E1k, Zden\u011Bk" . . . . "304883" . "[ED5C4FD1DFDC]" . "In the present invention, there are disclosed iron complex compounds in oxidation states +II and +III with salophene {2,2'-((1E,1'E)-(1,2-phenylenebis(azanylylidene))bis(methanylylidene))diphenolate (2-)} and additional N-donor heterocyclic ligands and their crystalline solvate, expressed by structural formulae I and II, wherein Xi1 to Xi4 represent an arbitrary combination of n methanylylidene groups and (4-n) azanylylidene groups, where n can range from 1 to 2, Ri1 to Ri8 represent a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an aryl group, a substituted aryl group, a hydroxy group and an amino group. Disclosed are also processes for preparing the above-described compounds, a pharmaceutical composition for use in medicine as well as a pharmaceutical composition for use as medicament for the treatment of tumor diseases."@en . . "RIV/61989592:15310/14:33153193" . "http://spisy.upv.cz/Patents/FullDocuments/304/304883.pdf" . . . "salophene, iron complexes, cancer. cytotoxicity"@en . "Prague" . . "\u0160indel\u00E1\u0159, Zden\u011Bk" . "43731" . "Komplexn\u00ED slou\u010Deniny \u017Eeleza v oxida\u010Dn\u00EDch stupn\u00EDch +II a +III se salophenem {2,2'-((1E,1'E)-(1,2-fenylenbis(azanylyliden))bis(methanylyliden))difenol\u00E1t(2-)} a dopl\u0148kov\u00FDmi N-donorov\u00FDmi heterocyklick\u00FDmi ligandy a jejich krystalosolv\u00E1ty, vyj\u00E1d\u0159en\u00E9 strukturn\u00EDmi vzorci I a II, kde X1 a\u017E X4 p\u0159edstavuje libovolnou kombinaci n methanylylidenov\u00FDch skupin a (4-n) azanylylidenov\u00FDch skupin, kde n m\u016F\u017Ee nab\u00FDvat hodnot 1 a\u017E 2, R1 a\u017E R8 p\u0159edstavuje atom vod\u00EDku, alkyl, substituovan\u00FD alkyl, alkenyl, aryl, substituovan\u00FD aryl, hydroxy a amino skupinu. Zp\u016Fsoby p\u0159\u00EDpravy t\u011Bchto slou\u010Denin, farmakologick\u00FD prost\u0159edek pro pou\u017Eit\u00ED v l\u00E9ka\u0159stv\u00ED a farmakologick\u00FD prost\u0159edek pro pou\u017Eit\u00ED jako l\u00E9\u010Diva pro l\u00E9\u010Dbu n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED." . "Salophenov\u00E9 komplexy \u017Eeleza s heterocyklick\u00FDmi N-donorov\u00FDmi ligandy, zp\u016Fsob jejich p\u0159\u00EDpravy a jejich pou\u017Eit\u00ED jako l\u00E9\u010Div v protin\u00E1dorov\u00E9 terapii" . "S" . . "\u00DA\u0159ad pr\u016Fmyslov\u00E9ho vlastnictv\u00ED" . . . "2014-11-12+01:00"^^ . "Salophenov\u00E9 komplexy \u017Eeleza s heterocyklick\u00FDmi N-donorov\u00FDmi ligandy, zp\u016Fsob jejich p\u0159\u00EDpravy a jejich pou\u017Eit\u00ED jako l\u00E9\u010Div v protin\u00E1dorov\u00E9 terapii" . . . . "Salophene iron complexes with heterocyclic N-donor ligands, process of their preparation and their use as medicaments in antitumor therapy"@en . . . "Komplexn\u00ED slou\u010Deniny \u017Eeleza v oxida\u010Dn\u00EDch stupn\u00EDch +II a +III se salophenem {2,2'-((1E,1'E)-(1,2-fenylenbis(azanylyliden))bis(methanylyliden))difenol\u00E1t(2-)} a dopl\u0148kov\u00FDmi N-donorov\u00FDmi heterocyklick\u00FDmi ligandy a jejich krystalosolv\u00E1ty, vyj\u00E1d\u0159en\u00E9 strukturn\u00EDmi vzorci I a II, kde X1 a\u017E X4 p\u0159edstavuje libovolnou kombinaci n methanylylidenov\u00FDch skupin a (4-n) azanylylidenov\u00FDch skupin, kde n m\u016F\u017Ee nab\u00FDvat hodnot 1 a\u017E 2, R1 a\u017E R8 p\u0159edstavuje atom vod\u00EDku, alkyl, substituovan\u00FD alkyl, alkenyl, aryl, substituovan\u00FD aryl, hydroxy a amino skupinu. Zp\u016Fsoby p\u0159\u00EDpravy t\u011Bchto slou\u010Denin, farmakologick\u00FD prost\u0159edek pro pou\u017Eit\u00ED v l\u00E9ka\u0159stv\u00ED a farmakologick\u00FD prost\u0159edek pro pou\u017Eit\u00ED jako l\u00E9\u010Diva pro l\u00E9\u010Dbu n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED."@cs . "Salophenov\u00E9 komplexy \u017Eeleza s heterocyklick\u00FDmi N-donorov\u00FDmi ligandy, zp\u016Fsob jejich p\u0159\u00EDpravy a jejich pou\u017Eit\u00ED jako l\u00E9\u010Div v protin\u00E1dorov\u00E9 terapii"@cs . . . . "Salophenov\u00E9 komplexy \u017Eeleza s heterocyklick\u00FDmi N-donorov\u00FDmi ligandy, zp\u016Fsob jejich p\u0159\u00EDpravy a jejich pou\u017Eit\u00ED jako l\u00E9\u010Div v protin\u00E1dorov\u00E9 terapii"@cs . "15310" . "3"^^ . "3"^^ . "RIV/61989592:15310/14:33153193!RIV15-MSM-15310___" . . "Tr\u00E1vn\u00ED\u010Dek, Zden\u011Bk" . "Univerzita Palack\u00E9ho v Olomouci" . . "Salophene iron complexes with heterocyclic N-donor ligands, process of their preparation and their use as medicaments in antitumor therapy"@en . . .